Edition:
India

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

65.20EUR
3:11pm IST
Change (% chg)

€-18.40 (-22.01%)
Prev Close
€83.60
Open
€75.50
Day's High
€76.55
Day's Low
€65.10
Volume
388,387
Avg. Vol
144,495
52-wk High
€126.85
52-wk Low
€65.10

Latest Key Developments (Source: Significant Developments)

Ipsen Appoints Steven Hildemann As Executive Vice President, Chief Medical Officer
Tuesday, 14 Jan 2020 

Jan 14 (Reuters) - Ipsen SA ::IPSEN APPOINTS STEVEN HILDEMANN, MD., PHD AS EXECUTIVE VICE PRESIDENT, CHIEF MEDICAL OFFICER.APPOINTMENT OF DR. STEVEN HILDEMANN AS EXECUTIVE VICE PRESIDENT, CHIEF MEDICAL OFFICER, HEAD OF GLOBAL MEDICAL AFFAIRS AND PHARMACOVIGILANCE EFFECTIVE MARCH 1, 2020.  Full Article

Ipsen Says Dysport® Now Approved In UK
Monday, 6 Jan 2020 

Jan 6 (Reuters) - Ipsen SA ::SAYS DYSPORT® NOW APPROVED IN THE UK FOR SYMPTOMATIC TREATMENT OF UPPER LIMB SPASTICITY IN CHILDREN WITH CEREBRAL PALSY.APPROVAL BASED ON THE PHASE III STUDY DEMONSTRATING THAT DYSPORT REDUCED SPASTICITY SYMPTOMS IN CHILDREN AGED TWO YEARS AND OLDER BEING TREATED FOR UPPER LIMB SPASTICITY DUE TO CEREBRAL PALSY.  Full Article

Ipsen Announces Departure Of David Meek As Chief Executive Officer
Wednesday, 18 Dec 2019 

Dec 18 (Reuters) - Ipsen SA ::IPSEN ANNOUNCES DEPARTURE OF DAVID MEEK AS CHIEF EXECUTIVE OFFICER.BOARD HAS ASKED NOMINATIONS COMMITTEE, CHAIRED BY CAROL XUEREF, TO IMMEDIATELY CONDUCT A SEARCH PROCESS IN ORDER TO IDENTIFY FUTURE CHIEF EXECUTIVE OFFICER..BOARD HAS DECIDED TO APPOINT AYMERIC LE CHATELIER, CURRENTLY CHIEF FINANCIAL OFFICER AS INTERIM CEO TO REPLACE DAVID MEEK AS OF JANUARY 1, 2020.  Full Article

Ipsen Initiates Partial Clinical Hold For Palovarotene IND120181 And IND135403 Studies
Friday, 6 Dec 2019 

Dec 6 (Reuters) - Ipsen SA ::IPSEN INITIATES PARTIAL CLINICAL HOLD FOR PALOVAROTENE IND120181 AND IND135403 STUDIES.FDA IS ALLOWING STUDIES TO CONTINUE TO TREAT PATIENTS 14 YEARS OF AGE AND OLDER.ALL SUBJECTS CURRENTLY PARTICIPATING IN STUDY WILL HAVE INTERRUPTION OF TREATMENT UNTIL FURTHER NOTICE.NO NEW PATIENTS WILL BE ENROLLED WHILE PARTIAL CLINICAL HOLD IS IN EFFECT.PARTIAL CLINICAL HOLD APPLIES TO PEDIATRIC POPULATION CURRENTLY PARTICIPATING IN PHASE 2 AND PHASE 3 STUDIES IN ALL CLINICAL SITES AT GLOBAL LEVEL.  Full Article

Proposed Reclassification Of Ipsen Shares Held By Mayroy
Tuesday, 5 Nov 2019 

Nov 5 (Reuters) - Ipsen SA ::PROPOSED RECLASSIFICATION OF IPSEN SHARES HELD BY MAYROY.MAYROY FILES A REQUEST WITH AMF FOR A WAIVER TO OBLIGATION TO FILE A PUBLIC OFFER.ANNE AND HENRI BEAUFOUR'S RESPECTIVE HOLDING COMPANIES WILL EACH HOLD 26.03% OF IPSEN'S SHARE CAPITAL AND 33.27% OF ITS VOTING RIGHTS.SCHWABE FAMILY WILL HOLD 4.34% OF CAPITAL AND 5.54% OF VOTING RIGHTS.  Full Article

Ipsen Q3 Sales Up 14.5% At 644.7 Million Euros
Thursday, 24 Oct 2019 

Oct 24 (Reuters) - Ipsen SA ::IPSEN DELIVERS STRONG DOUBLE-DIGIT SALES GROWTH FOR THE THIRD QUARTER OF 2019 AND CONFIRMS FULL YEAR 2019 GUIDANCE.FULL YEAR 2019 GUIDANCE CONFIRMED.Q3 2019 GROUP SALES GROWTH OF +16.0% AS REPORTED AND +14.5% AT CONSTANT EXCHANGE RATES AND CONSOLIDATION SCOPE.Q3 YTD GROUP SALES GROWTH OF +15.7%.Q3 2019 GROUP SALES GREW 14.5% TO €644.7 MILLION.  Full Article

Ipsen Announces FDA Approval Of Dysport® For The Treatment Of Upper Limb Spasticity In Children
Thursday, 26 Sep 2019 

Sept 26 (Reuters) - IPSEN SA ::IPSEN ANNOUNCES FDA APPROVAL OF DYSPORT® (ABOBOTULINUMTOXINA) FOR THE TREATMENT OF UPPER LIMB SPASTICITY IN CHILDREN, EXCLUDING CEREBRAL PALSY.DYSPORT IS FIRST AND ONLY FDA-APPROVED BOTULINUM TOXIN FOR TREATMENT OF BOTH PEDIATRIC UPPER AND LOWER LIMB SPASTICITY.MOST FREQUENT ADVERSE REACTIONS OBSERVED WERE UPPER RESPIRATORY TRACT INFECTION AND PHARYNGITIS.THIS APPROVAL EXCLUDES USE IN CHILDREN WITH UPPER LIMB SPASTICITY CAUSED BY CEREBRAL PALSY.  Full Article

Ipsen Sees 2019 Group Sales Growth Greater Than 14%
Thursday, 25 Jul 2019 

July 25 (Reuters) - Ipsen SA ::IPSEN DELIVERS STRONG RESULTS FOR THE FIRST HALF OF 2019 WITH ROBUST DOUBLE-DIGIT SALES GROWTH AND IMPROVED CORE OPERATING MARGIN AND UPGRADES ITS GUIDANCE FOR FULL YEAR 2019.H1 OPERATING INCOME EUR 317.8 MILLION VERSUS EUR 269.7 MILLION YEAR AGO.GROUP SALES GROWTH GREATER THAN +14.0% AT CONSTANT CURRENCY AND CONSOLIDATION SCOPE.UPGRADED FULL YEAR 2019 GUIDANCE.H1 GROUP SALES NET EUR 1.23 BILLION VERSUS EUR 1.06 BILLION YEAR AGO.H1 CORE OPERATING MARGIN AT 31.5% OF NET SALES, UP 1.2 POINTS AND CORE OPERATING INCOME GROWTH OF 20.1% AFTER HIGHER RESEARCH AND DEVELOPMENT INVESTMENTS INCLUDING CLEMENTIA.FOR FY 2019 SEES GROUP SALES GROWTH GREATER THAN +14.0% AT CONSTANT CURRENCY AND CONSOLIDATION SCOPE (VERSUS INITIAL GUIDANCE OF GREATER THAN +13.0%).H1 CONSOLIDATED NET PROFIT EUR 220.6 MILLION VERSUS EUR 197.3 MILLION YEAR AGO.SEES 2019 CORE OPERATING MARGIN AT AROUND 30.0% OF NET SALES.  Full Article

Ipsen And Servier Announce Initial Phase 1/2 Clinical Data
Friday, 5 Jul 2019 

July 5 (Reuters) - IPSEN SA ::AND SERVIER ANNOUNCE INITIAL PHASE 1/2 CLINICAL DATA EVALUATING LIPOSOMAL IRINOTECAN (ONIVYDE).APPROXIMATELY THREE QUARTERS OF PATIENTS (71.9%) ACHIEVED DISEASE CONTROL AT WEEK 16, WHILE 34% HAD A RESPONSE (SECONDARY ENDPOINT).71.9% (23/32) OF STUDY PATIENTS IN THE 50/60 PP ACHIEVED DISEASE CONTROL AT 16 WEEKS.TREATMENT EMERGENT ADVERSE EVENTS GRADE 3 OR HIGHER WERE REPORTED BY 20 OF 32 PATIENTS FROM THE 50/60 DOSE POOLED PATIENT ANALYSIS; NO PATIENT REPORTED GRADE 3 OR HIGHER FATIGUE OR PERIPHERAL NEUROPATHY (PRIMARY ENDPOINT).  Full Article

Ipsen Announces FDA Approval For Pre-Filled Syringe For Somatuline Depot
Tuesday, 25 Jun 2019 

June 24 (Reuters) - Ipsen SA ::IPSEN ANNOUNCES U.S. FDA APPROVAL FOR NEWLY DESIGNED PRE-FILLED SYRINGE FOR SOMATULINE® DEPOT (LANREOTIDE).IPSEN BIOPHARMACEUTICALS - HEALTHCARE PROVIDERS CAN EXPECT TO RECEIVE NEW SYRINGE DURING Q3 2019.  Full Article

Ipsen's CEO resigns, to join Ferring unit

Dec 18 French healthcare company Ipsen said on Wednesday its chief executive officer, David Meek, has resigned and will take the helm at FerGene, a unit of Swiss drug company Ferring Pharmaceuticals.